Neurology: A joint study by top U.S. universities found risk factors for hereditary Alzheimer's disease

Micro-bleeding (CMHs) or micro-bleeding (CMBs), i.e. small brain haemorrhages, are common in the elderly, especially with dementia.
these lesions are usually associated with: 1) hypertension, 2) blood vessels associated with Alzheimer's disease (AD) or cerebral amyloid vascular disease β (CAA), A-amyloid protein (A beta), 3) AD clinical trials of A-beta-altering therapy ().
the baseline, the presence of CMHs foreshadows more CMHs in the general population and in AD.
, in trials of A-beta-modification therapy, the FDA recommended monitoring CMHs and excluding five or more CMHs participants.
because older participants often have mixed pathology, it is difficult to distinguish or determine which of these three factors is the cause of CMHs, especially in treatment trials.
evaluating a young queue, such as individuals with dominant genetic AD (dominant inherited AD, DIAD), where blood pressure is relatively normal and un treated, may help describe the natural development of CMHs associated with AD's uniqueness.
by observing changes in treatment trials in patients with DIAD, which could help better understand the meaning of CMHs, Nelly Joseph-Mathurin of the University of Washington and others used data from the explicit genetic Alzheimer's Network (DIAN) to Amyloid-relatedimaging abnormalities, ARIA-H) is evaluated and tracked over a long period of time to identify clinical risks associated with CMHs and to identify characteristics of high-risk individuals with hemorrhagic amyloid-associated imaging abnormalities (ARIA-H).
they included mutant carriers (n-310) and non-carriers (n-201) and performed neuroimaging tests, including gradient echo MR sequence detection CMHs, neuropsychology, and clinical evaluation.
relationship between CMHs and neuroimaging and clinical markers of disease was evaluated by cross-sectional and longitudinal analysis.
showed that 3% of non-carriers and 8% of carriers had CMHs, mainly in the brain leaf region.
carriers with CMHs were older, had higher espressosis and Hachinski ischemia scores, and had more clinical, cognitive, and motor impairments than those without CMH.
APOE-4 status is independent of the prevalence or prevalence of CMHs.
old or new CMHs can predict faster changes in clinical dementia ratings.
, the presence of two or more CMHs over time is associated with significant risk of additional CMHs development (8.95±10.04 per year).
significance of this study is the discovery of factors associated with the occurrence of CMHs.
CMHs are part of the underlying disease process of DID and are significantly associated with dementia.
participants who received the drug treatment trial may be at risk of ARIA-H as a complication, separating the natural incidence of CMHs from the drug-related CMHs can be challenging.
original source; Longitudinal Gain of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease; Nelly Joseph-Mathurin, Guoqiao Wang, et al.,Neurology Jan 2021, 10.1212/WNL.0000000000011542; DOI: 10.1212/WNL.00000000000011542Freeman Source: MedSci Original Copyright Notice: All noted on this website "Source: Met Medical" or "Source: MedSci Original" text, images and audio and video materials, copyrights are owned by Metz Medicine, without authorization, no media, website or individual may reproduce, authorized to reproduce with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here